Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Vertex Pharmaceuticals Cash Provided by (Used in) Investing Activity, Including Discontinued Operation decreased by 49.9% to -$431.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 674.0%, from -$55.80M to -$431.90M. Over 3 years (FY 2021 to FY 2025), Cash Provided by (Used in) Investing Activity, Including Discontinued Operation shows a downward trend with a 40.5% CAGR.
Analysis
How to read this metric
Negative values typically indicate aggressive reinvestment or acquisition activity, while positive values may suggest divestment or maturity of investment portfolios.
Detailed definition
The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the p...
Peer comparison
Standard line item in the Statement of Cash Flows for all public companies.
other_net_cash_provided_by_used_in_investing_activitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$79.70M | -$52.90M | -$134.00M | -$51.00M | -$61.50M | -$384.20M | -$785.43M | -$785.43M | -$785.43M | -$785.43M | -$2.14B | -$463.70M | -$348.00M | -$821.90M | -$55.80M | -$484.50M | -$117.00M | -$288.10M | -$431.90M |
| QoQ Change | — | +33.6% | -153.3% | +61.9% | -20.6% | -524.7% | -104.4% | +0.0% | +0.0% | +0.0% | -172.0% | +78.3% | +25.0% | -136.2% | +93.2% | -768.3% | +75.9% | -146.2% | -49.9% |
| YoY Change | — | — | — | — | +22.8% | -626.3% | <-999% | <-999% | -104.4% | — | -172.0% | +41.0% | +55.7% | -4.6% | +97.4% | -4.5% | +66.4% | +64.9% | -674.0% |
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation?
- Vertex Pharmaceuticals (VRTX) reported cash provided by (used in) investing activity, including discontinued operation of -$431.90M in Q1 2026.
- How has Vertex Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
- Vertex Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation decreased by 674.0% year-over-year, from -$55.80M to -$431.90M.
- What is the long-term trend for Vertex Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation has grown at a 40.5% compound annual growth rate (CAGR), from -$340.90M to -$945.40M.
- What does cash provided by (used in) investing activity, including discontinued operation mean?
- The total net cash spent on or generated from investments in assets and securities.